NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.
Dr. Seymour will review the Company’s recent in vivo studies against influenza. The success of these studies has led the Company to consolidate its anti-influenza drug programs into a single, pan-influenza drug, “FluCide™”. This single drug is expected to be highly effective against all forms of influenza A, including the recent “swine flu” 2009/CA/H1N1 strain, seasonal flu strains, as well as H5N1 bird flu strains feared to be capable of creating a devastating pandemic, and other highly pathogenic strains on the horizon.